Ranolazine for atrial fibrillation: Buy one get three beneficial mechanisms!

European Journal of Heart Failure

Volumn 14, Issue 12, 2012, Pages 1313-1315

  Maier, Lars S ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL L TYPE; POTASSIUM; RANOLAZINE; SODIUM CALCIUM EXCHANGE PROTEIN;

CALCIUM CURRENT; DELAYED AFTERDEPOLARIZATION; EARLY AFTERDEPOLARIZATION; EDITORIAL; EXPERIMENTAL RABBIT; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART MUSCLE POTENTIAL; HEART VENTRICLE CONDUCTION; HEART VENTRICLE OVERLOAD; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POTASSIUM CURRENT; PRIORITY JOURNAL; REFRACTORY PERIOD; SARCOPLASMIC RETICULUM;

ACETANILIDES; ANIMALS; ATRIAL FIBRILLATION; ENZYME INHIBITORS; FEMALE; HEART FAILURE; PIPERAZINES;

EID: 84870397152     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs168     Document Type: Editorial

References (15)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; ESC Committee for. Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. EurJ Heart Fail 2012;14:803-869.
2. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium selective sodium channel block as a strategy for suppression of atrial fibrillation:; differences in sodium channel inactivation between atria and ventricles and the I role of ranolazine. Circulation 2007;116:1449-1457.
3. Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther 2012;133:311-323.
4. + cur. rents in atrial fibrillation: effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010;55:2330-2342.
5. Aidonidis I, Doulas K, Hatziefthimiou A, Tagarakis G, Simopoulos V, Rizos I, Tsilimingas N, Molyvdas PA. Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits. J Cardiovasc Pharmacol Ther 2012;in press.
6. Frommeyer G, Schmidt M, Clauß C, Kaese S, Stypmann J, Pott C, Eckardt L, Milberg P. Further insights into the underlying electrophysiological mechanisms] for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. EurJ Heart Fail 2012;14:1322-1331.
7. Frommeyer G, Milberg P, Witte P, Stypmann J, Koopmann M, Lücke M, Osada N, Breithardt G, Fehr M, Eckardt L A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. EurJ Heart Fail 2011;13:1060-1069.
8. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial; fibrillation. Circulation 1995;92:1954-1968.
9. Nattel S, Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 2012;33:1870-1877.
10. 2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res 2010;106:1134-1144.
11. 2+ exchanger function underlie delayed afterde-polarizations in patients with chronic atrial fibrillation. Circulation 2012;125: 2059-2070.
12. Lemoine MD, Duverger JE, Naud P, Chartier D, Qi XY, Comtois P, Fabritz L, Kirchhof P, Nattel S. Arrhythmogenic left atrial cellular electro-physiology in a murine genetic long QT syndrome model. Cardiovasc Res 2011;92:67-72.
13. Sicouri S, Blazek J, Belardinelli L, Antzelevitch C. Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine. Circ Arrhythm Electrophysiol 2012;5:371-379.
14. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, Braunwald E. Effect of ranola-zine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116: 1647-1652.
15. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010;56:1216-1224.